These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1313 related items for PubMed ID: 19361748

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 4. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens.
    Koh LP, Chao NJ.
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):1-22. PubMed ID: 14752775
    [Abstract] [Full Text] [Related]

  • 5. Costs of pediatric allogeneic hematopoietic-cell transplantation.
    Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ.
    Pediatr Blood Cancer; 2010 Jan; 54(1):138-43. PubMed ID: 19693941
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T, Isola LM.
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [Abstract] [Full Text] [Related]

  • 9. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R, Harbi S, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Etienne A, Calmels B, Lemarie C, Prebet T, Granata A, Charbonnier A, Rey J, Chabannon C, Faucher C, Vey N, Blaise D.
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [Abstract] [Full Text] [Related]

  • 10. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
    Johnston L.
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):177-92. PubMed ID: 18503985
    [Abstract] [Full Text] [Related]

  • 11. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.
    Jacobsohn DA, Hewlett B, Ranalli M, Seshadri R, Duerst R, Kletzel M.
    Bone Marrow Transplant; 2004 Nov; 34(10):901-7. PubMed ID: 15361908
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
    Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
    [Abstract] [Full Text] [Related]

  • 15. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
    Malard F, Milpied N, Blaise D, Chevallier P, Michallet M, Lioure B, Clément L, Hicheri Y, Cordonnier C, Huynh A, Yakoub-Agha I, Peffault de Latour R, Mohty M.
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1059-67. PubMed ID: 25708220
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
    van Heeckeren WJ, Fanning LR, Meyerson HJ, Fu P, Lazarus HM, Cooper BW, Tse WW, Kindwall-Keller TL, Jaroscak J, Finney MR, Fox RM, Solchaga L, Forster M, Creger RJ, Laughlin MJ.
    Br J Haematol; 2007 Nov; 139(3):464-74. PubMed ID: 17910637
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.
    Ballen KK, Joffe S, Brazauskas R, Wang Z, Aljurf MD, Akpek G, Dandoy C, Frangoul HA, Freytes CO, Khera N, Lazarus HM, LeMaistre CF, Mehta P, Parsons SK, Szwajcer D, Ustun C, Wood WA, Majhail NS.
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1819-27. PubMed ID: 25064747
    [Abstract] [Full Text] [Related]

  • 20. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
    Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ, Suffredini A, Childs R.
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):542-50. PubMed ID: 15983554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.